Phase
Condition
Scar Tissue
Amyotrophic Lateral Sclerosis (Als)
Myasthenia Gravis (Chronic Weakness)
Treatment
N/AClinical Study ID
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
age between 18 and 75 years
diagnosis of ALS according to revised El Escorial criteria and Awaji-Shima criteria
disease duration < 24 months
ALSFRS-R > 30 at the recruitment
ALSFRS-R decline > 1 in the at least 3-months period before the intervention
normal respiratory functionality (FVC > 80% and ALSFRS-R items 10,11,12 > 4) at therecruitment
treatment with riluzole 50 mg x 2/die
Exclusion
Exclusion Criteria:
inclusion in other clinical trials
presence of tracheotomy or/and PEG (percutaneous endoscopic gastrostomy)
contraindications to magnetic fields exposure
pregnancy or breast-feeding
history of epilepsy or seizures
assumption of drugs acting on central nervous system, except for antidepressive drugsand benzodiazepines.
cognitive impairment
lack of informed consent
Study Design
Connect with a study center
Department of Neurology and Laboratory of Neuroscience, Istituto Auxologico Italiano, IRCCS
Milan,
ItalyActive - Recruiting
Neurology Unit, Campus Biomedico University
Rome, 00128
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.